High-grade
gliomas are the most common primary
tumors in the central nervous system (CNS) in adults. Despite efforts to improve treatment by combination
therapies (neurosurgery, radio- and
chemotherapy), high-grade
glioma patients still have a grim prognosis, indicating an urgent need for new therapeutic approaches. The molecular processes of gliomagenesis are being unraveled, and novel targeted therapeutic strategies to defy high-grade
gliomas are emerging.
Transforming growth factor-beta (TGF-β), in particular the TGF-β2
isoform, has been identified as a key factor in the progression of
malignant gliomas. TGF-β2, originally described as "
glioblastoma-derived T-cell suppressor factor", is associated with the immuno-suppressed status of patients with
glioblastoma, and is therefore responsible for loss of
tumor immune surveillance. Elevated TGF-β2 levels in
tumors and in the plasma of patients have been associated with advanced disease stage and poor prognosis. Consequently, a targeted strategy to modulate TGF-β2 signaling is highly promising. The
antisense oligonucleotide trabedersen (
AP 12009) that specifically blocks TGF-β2
mRNA will be the main focus of this review. In three phase I/II studies and a randomized, active-controlled dose-finding phase IIb study,
trabedersen treatment of high-grade
glioma patients with recurrent or refractory
tumor disease led to long-lasting
tumor responses and so far promising survival data. On the basis of these data the currently ongoing phase III study SAPHIRRE was initiated.